BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics

BCRX POWR Grades

• Value is the dimension where BCRX ranks best; there it ranks ahead of 67.99% of US stocks.
• BCRX's strongest trending metric is Stability; it's been moving down over the last 179 days.
• BCRX's current lowest rank is in the Stability metric (where it is better than 1.92% of US stocks).

BCRX Stock Summary

• Biocryst Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 3.78% of US listed stocks.
• BCRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.19% of US stocks.
• As for revenue growth, note that BCRX's revenue has grown 782.38% over the past 12 months; that beats the revenue growth of 98.72% of US companies in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Biocryst Pharmaceuticals Inc are CYTK, VERU, LOGC, EXEL, and DNN.
• Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.

BCRX Valuation Summary

• In comparison to the median Healthcare stock, BCRX's EV/EBIT ratio is 155.97% lower, now standing at -16.4.
• Over the past 243 months, BCRX's EV/EBIT ratio has gone down 11.7.
• BCRX's EV/EBIT ratio has moved down 11.7 over the prior 243 months.

Below are key valuation metrics over time for BCRX.

BCRX Growth Metrics

The 2 year net income to common stockholders growth rate now stands at -49.27%.
• The 5 year net income to common stockholders growth rate now stands at -127.75%.
• Its 2 year revenue growth rate is now at 142.19%.

Over the past 52 months, BCRX's revenue has gone up $126,891,000.

The table below shows BCRX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	157.17	-142.157	-184.062
2021-09-30	114.028	-154.337	-226.776
2021-06-30	79.136	-169.316	-214.09
2021-03-31	32.048	-174.946	-209.499
2020-12-31	17.812	-137.216	-182.814
2020-09-30	53.521	-103.025	-124.943

BCRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BCRX has a Quality Grade of C, ranking ahead of 64.73% of graded US stocks.
• BCRX's asset turnover comes in at 0.295 -- ranking 153rd of 682 Pharmaceutical Products stocks.
• BLCM, VIRX, and GLYC are the stocks whose asset turnover ratios are most correlated with BCRX.

The table below shows BCRX's key quality metrics over time.